Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

Inclusion Criteria:

   - Unresectable or metastatic soft tissue sarcoma

   - ≥ 1 prior systemic therapy for sarcoma, including adjuvant systemic therapy

   - Age ≥ 18 years

   - 4 Life expectancy > 3 months

   - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

   - Lab values as below:

Absolute neutrophil count (ANC) ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3; Creatinine ≤ 1.5
x upper limit of normal (ULN) OR calculated (calc.); creatinine clearance > 45 mL/min using
the lean body mass formula only; Total bilirubin ≤ 1.5 x ULN in absence of Gilbert disease
(total bilirubin ≤ 3 x ULN with Gilbert); also, if hyperbilirubinemia is clearly attributed
to liver metastases total bilirubin ≤ 3 x ULN is permitted AST/ALT ≤ 3 x ULN;Thyroid
stimulating hormone (TSH) within normal limits (WNL);supplementation is acceptable to
achieve a TSH WNL; in subjects with abnormal TSH if free T4 is normal and subject is
clinically euthyroid, subject is eligible

   - Any toxic effects of prior therapy (except alopecia) must be resolved to NCI CTCAE,
   version 5.0, Grade 1 or less

   - Ability to understand and the willingness to sign a written informed consent

   - Women of childbearing potential (WOCBP) receiving nivolumab must be willing to adhere
   to contraception for a period of 5 months after the last dose of nivolumab. Men
   receiving nivolumab and who are sexually active with WOCBP will be instructed and must
   be willing to adhere to contraception for a period of 7 months after the last dose of
   nivolumab.

Exclusion Criteria:

   - Prior therapy with ipilimumab or nivolumab, or any agent targeting programmed cell
   death 1 (PD-1), PD-L1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

History of the following:

   - Active known or suspected autoimmune disease

   - Known human immunodeficiency virus (HIV) (Subjects with lymphocytes > 350 cluster of
   differentiation (CD)4+ cells and no detectable viral load are eligible)

   - Hepatitis B

Hepatitis B can be defined as:

Hepatitis B surface antigen (HBsAg) > 6 months Serum hepatitis B virus (HBV)
deoxyribonucleic acid (DNA) 20,000 IU/mL (105 copies/mL), lower values 2,000 to 20,000
IU/mL (104 to 105 copies/mL) are often seen in hepatitis B-e antigen (HbeAg)-negative
chronic hepatitis B Persistent or intermittent elevation in alanine aminotransferase
(ALT)/alanine aminotransferase (AST) levels. Liver biopsy showing chronic hepatitis with
moderate or severe necroinflammation

   - Hepatitis C Hepatitis C antibody (Ab) positive Presence of hepatitis C virus (HCV)
   ribonucleic acid (RNA) 3.2.2.5 Known active pulmonary disease with hypoxia defined as:
   Oxygen saturation < 85% on room air or Oxygen saturation < 88% despite supplemental
   oxygen

   - Systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents)
   or other immunosuppressive medications within 7 days of registration

   - Received any live/attenuated vaccine (eg, varicella, zoster, yellow fever, rotavirus,
   oral polio and measles, mumps, rubella (MMRI) within 30 days before initiation of
   treatment on this protocol.

   - If female, pregnant or lactating. (Women of childbearing potential are required to
   have a negative pregnancy test within 24 hours prior to the initial administration of
   study drug)